2726 results about "Nicotinamide" patented technology

Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and / or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.

The invention provides a plant nutrient solution for soilless culture of tomato. The plant nutrient solution is prepared by the following raw materials in part by weight: 2 to 4 parts of potassium nitrate, 3 to 8 parts of calcium nitrate, 1 to 5 parts of magnesium sulfate, 1 to 3 parts of potassium phosphate, 1 to 2 parts of potassium sulphate, 1 to 2 parts of monopotassium phosphate, 0.1 to 0.15 part of Na2-EDTA, 0.05 to 0.1 part of Fe-EDTA, 0.01 to 0.05 part of molybdic acid, 0.01 to 0.03 part of manganese sulfate, 0.3 to 0.5 part of sodium tetraborate, 2 to 4 parts of superphosphate, 0.003 to 0.01 part of zinc sulfate, 0.001 to 0.002 part of copper sulfate, 0.001 to 0.003 part of ammonium nitrate, 1 to 3 parts of urea, 1 to 2 parts of organic acid, 0.5 to 1 part of beta cyclodextrin, 0.05 to 0.1 part of vitamin B, 2 to 4 parts of chitosan, 1 to 2 parts of nicotinamide, 0.5 to 2 parts of amino acid, 0.3 to 0.5 part of diethyl aminoethyl hexanoate, 0.02 to 0.5 part of gibberellin, and 5,000 to 7,000 parts of water. According to experiment, the plant nutrient solution provided by the invention can be used for carrying out soilless culture of tomato, and the tomato has high plant height, thick stem, high cluster and high output.

The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more proteins selected from the group consisting of NPT1, PNC1, NMA1 and NMA2. Another method comprises modulating the level of nicotinamide in the cell.

The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.

The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.

The present invention provides compositions and methods for use in the treatment of hyperproliferative dermal diseases. Specifically, the present invention teaches pharmaceutical compositions for topical administration where the compositions contain nicotinamide and a vitamin D metabolite, calcipotriol, which are particularly effective in treating and in the maintenance treatment of psoriasis and other related dermal disorders and diseases.

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001" / >(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup

The invention discloses a plant polysaccharide cigarette filter tip and a preparation method thereof. Plant polysaccharide, starch, adsorbent, plasticizer, emulsifier, waterproofing agent and plant protein are blended according to a certain proportion, so that the filter tip is prepared. The preparation method includes the following steps: (a) the starch, water and the plasticizer are blended and stirred, so that modified starch solution is obtained; (b) the plant polysaccharide and the modified starch solution are blended; (c) under certain conditions, the emulsifier, the waterproofing agent and the adsorbent are added into the mixture of the plant polysaccharide and the modified starch solution, and after stirring, the mixture is injected into a long cylindrical mold made of anti-freezing, heat-proofing material and molded; (d) the semifinished product is placed into a freezing environment and frozen, i.e. prefreezing; (e) the semifinished product in step d is placed into a freeze dryer and freeze-dried; (f) the porous composite body is taken out of the mold and deburred, and thereby a filter tip stick is obtained. Material resources are rich, the cost is low, and the three wastes cannot be produced. The performance is good, the filter tip can reduce the nicotine content by 40.2 to 84.1 percent, the tar by 26 to 72.1 percent and the nicotinamide by 20 to 39.2 percent, and after use, waste can be biodegraded.

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where m, n, p, V, R1, R2, R3, R4, R5 and R6 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGFβ superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGFβ superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.

The invention discloses an external skin care product capable of adjusting skin immunity and delaying skin aging. The external skin care product is characterized by comprising powder, an aqueous solution and emulsion, wherein the powder comprises oligopeptide-1 and ginsenoside; the aqueous solution comprises glycyrrhiza glabra root extract, artemisia capillaris flower extract, mulberry root extract, jujube fruit extract, scutellaria root extract, hydrolyzed rice protein and nicotinamide; and the emulsion comprises hgytantriol bifida ferment lysate, creatine, carnosine, alpha glucosyl hesperidin, hexapeptide-3, centella asiatica extract, coenzyme Q10 inclusion complex, opuntia ficus-indica stem extract, rhodiola rosea extract, saussurea involucrate extract, pseudo-ginseng root extract and Chinese angelica extract inclusion complex. According to the external skin care product, the powder, the aqueous solution and the emulsion are jointly used, and the external skin care product can reduce wrinkle and pachulosis, even skin tone and improve skin elasticity and skin firmness, so that the skin is finer and smoother and looks young.

The invention discloses functional fatty powder and a preparation method thereof, and belongs to the technical field of feeds. The functional fatty powder is characterized in that raw materials comprise the following components in parts by weight: 30-50 parts of concentrated omega-fatty acid fat, 10-20 parts of lecithin, 8-15 parts of concentrated linolenic acid fat, 8-15 parts of MCT, 1-5 parts of choline, 1.5-5.5 parts of nicotinamide, 1-5 parts of a composite emulsifying agent, 3-8 parts of a composite antioxidant, 2-8 parts of vitamin C, and 40-70 parts of encrusting substances or 30-60 parts of carriers. The functional fatty powder provided by the invention is small in addition quantity, high in cost performance ratio, good in stability, high in nutrient value and high in fat utilization rate; the functional fatty powder not only can greatly improve the growing property and the reproductive property of animals but also can improve the immunity of the animals and promote the development of animal organisms, so that the functional fatty powder is an excellent feed additive.

The invention discloses whitening and freckle-removing cream. The cream is mainly prepared from glycerin, ethylhexyl palmitate, caprylic / capric triglyceride, isononyl isononanoate, polydimethylsiloxane, 1,2-pentanediol, butyrospermum parkii butter, 1,2-hexanediol, caprylyl glycol, cetostearyl alcohol, carbomer, xanthan gum, nicotinamide, arginine, rosa damascena flower oil, citrus medica L. extract, cucumis sativus fruit extract, bearberry leaf extract, rose extract, sodium hyaluronate, methyl glucose sesqui-stearate, PEG-20 methyl glucose sesqui-stearate, glyceryl stearate, phenoxyethanol and water. A natural cosmetic is prepared from whitening components of natural plants and directly acts on the facial skin, so that the effective ingredients permeate into the basal layer of the skin to reduce and decompose existing melanin, activate cells and diminish facial freckles; and the natural cosmetic is reasonable in compatibility, so that the skin is whitened and moistened and has delicate sheen.

The invention discloses a recombinant microorganism for preparing dharma diene and protopanoxadiol and a construction method of the recombinant microorganism. The construction method of the recombinant bacteria comprises a step of adding dharma diene synthase, protopanoxadiol synthase and nicotinamide adenine dinucleotide phosphate - cytochrome P450 reductase encoding gene into saccharomyces cerevisiae to obtain recombinant bacteria I. According to the recombinant microorganism for preparing the dharma diene and the protopanoxadiol and the construction method of the recombinant microorganism, by means of homologous recombination, the dharma diene synthase, the protopanoxadiol synthase and the nicotinamide adenine dinucleotide phosphate - the cytochrome P450 reductase encoding gene are all added into the saccharomyces cerevisiae to obtain the initial recombinant bacteria, and the effect that the initial recombinant bacteria can produce trace amount of the dharma diene and trace amount of the protopanoxadiol is discovered; tHMG1 activity of the initial recombinant bacteria is further improved, and therefore intermediate recombinant bacteria are obtained, and by means of the intermediate recombinant bacteria, the yield of the dharma diene and the yield of the protopanoxadiol are significantly increased; the activity of one or two or three of ERG1, ERG9 and ERG20 are improved on the basis of the intermediate recombinant bacteria, and the effect that the recombinant bacteria which can be used to increase the yield of the dharma diene and the yield of the protopanoxadiol are constructed is also discovered. By means of the recombinant microorganism for preparing the dharma diene and the protopanoxadiol and the construction method of the recombinant microorganism, the foundation is laid for artificially synthesizing the dammar diene and the protopanoxadiol.

Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and / or functionality of NK cells by treating the cells with a nicotinamide or other nicotinamide moiety in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof.

The invention discloses a whitening composition and a skin care product with the same. The whitening composition and the skin care product contain glycyrrhiza glabra extracts, arbutin and 3-o-ethyl ascorbic acid, and preferably contain nonapeptide-1, nicotinamide, ethylhexyl methoxycinnamate or composition of the nonapeptide-1, the nicotinamide and the ethylhexyl methoxycinnamate. Through mechanism analysis, the composition has the advantages that possibly due to the mutual action and influence among various ingredients, the generation of melanin is inhibited through inhibiting the activity of tyrosinase; the migration of melanocytes to the skin is retarded; in addition, the plant and microbial peptide sourced whitening ingredients and various antiallergic ingredients are selected to be combined to obtain the safe and mild whitening effect.

The invention relates to a method for measuring alkaloid in tobacco and tobacco products, which is characterized by dissociating alkaloid from the tobacco and tobacco products by using sodium hydroxide solution, extracting the alkaloid from samples by using triethylamine / trichloromethane solution, and detecting content of five kinds of alkaloid with GC-MS ( Gas Chromatograph-Mass Spectrum) quantitative analysis. Compared with other methods for analyzing the alkaloid, the invention has the advantages that alkaloid is separated from the tobacco by DB-35MS chromatographic columns so as to separate nornicotine and myosmine in the tobacco and accurately quantify target matters; batch sampling is carried out on the separation of nicotinamide and other alkaloid so as to detect the nicotinamide with high content in the tobacco and meet the quantitative analysis of other alkaloid with low content; the standard working curves of standard matters are separately compounded so as to avoid influence on quantization of other alkaloid by alkaloid catabolite existing in the standard samples. The method is simple and convenient and has the advantages of good repeatability, high analyzing and measuring sensitivity, and accurate quantization.

The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD+ glycohydrolase activity.

A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating tyrosine kinase-associated disease states in a subject using a compound of formula (I) is also described.

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more proteins selected from the group consisting of NPT1, PNC1, NMA1 and NMA2. Another method comprises modulating the level of nicotinamide in the cell.

Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.

The invention provides a drink composition containing L-carnitine, plant extracts and water. The plant extracts are selected from barley seedling, barley or fried barley, chrysanthemum, honeysuckle, arabian jasmine flower, tea flower, bamboo leaf flavonoid, eucommia ulmoides male flower, medlar, herba houttuyniae and the like; furthermore, the drink composition also contains inositol, taurine, lysine or lysinate, caffeine, nicotinamide, vitamin B6 and vitamin B12. The invention further provides a preparation method of the drink composition, as well as application of the drink composition in preparation of drinks for supplementing the L-carnitine by oral administration, and burning fat to reduce weight, removing grease and cleansing the palate, clearing away heat and toxic materials, refreshing and relieving summer-heat, refreshing, resisting fatigue, improving appetite and promoting digestion, protecting cardio-cerebral vessels, regulating immunity, resisting fatigue and oxidation, protecting liver and treating fatty liver. According to the novel functional drink containing L-carnitine nutrition and the plant extracts, provided by the invention, the plant extracts and the L-carnitine are matched to realize cooperative nutrient and health functions.

The invention discloses a compound anti-wrinkle anti-aging essence containing a plurality of small molecular peptides and a preparation method of the essence. The essence comprises the following raw materials in percentage by weight: 0.1-0.2% of sodium hyaluronate; 0.2-0.3% of acrylic acid (ester) / C10-30 alkanol acrylate cross-linked polymer; 5-7% of glycerol; 4-6% of 1,3-butanediol; 0.3-0.5% ofdipeptide diaminobutyl benzyl amide diacetate; 0.2-0.3% of palmitoyl tetrapeptide-5; 0.3-0.5% of palmitoyl tripeptide-1; 0.3-0.5% of palmitoyl pentapeptide-4; 0.1-0.3% of carnosine; 0.1-0.3% of serine; 0.1-0.3% of arginine; 0.1-0.3% of nicotinamide; 0.2-0.3% of a preservative and the rest of deionized water. The skin of a human body is repaired in an all-round way, so that good and rapid wrinkle removal and aging resistance effects are achieved.

The invention discloses a novel method for preparing beta-nicotinamide mononucleotide (beta-NMN). According to the method, D-5-ribose phosphate, ATP and nicotinamide are used as raw materials, beta-nicotinamide mononucleotide can be efficiently and biologically synthesized by catalysis of immobilized whole-cell containing phosphoribosylpyrophosphate synthetase and nicotinamide phosphoribosyltransferase, and the concentration of the synthesized beta-nicotinamide mononucleotide can be 13.3g / L, so that the synthetic amount and conversion rate of beta-NMN enzymatic reaction can be increased, the immobilized whole-cell can be used repeatedly, and the reaction complexity and production cost can be reduced.

Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition, such as, for example, inflammatory disease, and pharmaceutical compositions comprising such compounds.

The invention relates to a preparation method of nicotinamide adenine dinucleotide, which comprises the following steps of: with 1,2,3,5-tetraacetyl-beta-D-ribofuranose as a starting raw material, preparing nicotinamide mononucleotide through sequentially a condensation reaction, an ammonolysis reaction and a phosphorylation reaction; and then mixing the prepared nicotinamide mononucleotide with adenosine triphosphate, generating an enzymic catalytic reaction in the presence of nicotinamide adenosine nucleotide transferase and pyrophosphatase to prepare the nicotinamide adenine dinucleotide. Compared with the prior art, the technical scheme provided by the invention has the advantage that the whole process is simplified and optimized by combination of a chemical method and an enzymic method.

The invention discloses a recombinant human NADH (nicotinamide-adenine dinucleotid) dehydrogenase subunit-4 gene and a constructing method of an expression vector thereof. The nucleotide sequence of the gene is shown in SEQ ID NO:1, and the size of the nucleotide sequence is 2889 bp. The constructing steps of adeno-associate virus vectors are as follows: firstly constructing a recombinant adeno-associated virus vector containing the human NADH dehydrogenase subunit-4 gene, and then coating, infecting, purifying, concentrating and identifying the recombinant adeno-associated virus. According to the method, the recombinant adeno-associated virus vector with the recombinant human NADH dehydrogenase subunit-4 gene can be quickly and simply constructed, and is packaged to obtain the adeno-associated virus vector with complex defects. The gene can be used for gene therapy of LHON (leber's hereditary optic neuropathy).

A method of stabilizing R-α-lipoic acid includes combining R-α-lipoic acid with nicotinamide in a weight ratio between about 10:4 to about 10:8. A composition for treating oxidative stress includes R-α-lipoic acid and nicotinamide in a weight ratio of between about 10:4 and about 10:8.

A synthetic process is provided for the preparation of phosphorylated analogs of nicotinamide riboside (“NR”) having the formula (I), or salts thereof, and reduced or modified derivatives thereof, having the formula (II), wherein X−, Y1, Y2, Z1, Z2, n, R1, R2, R3, R4, R5, R6, and R7 are as defined herein. The present disclosure also relates to the preparation of phosphorylated analogs of nicotinic acid riboside (“NAR”) having the formula (I), or salts thereof, and reduced or modified derivatives thereof, having the formula (II). Generally solvent-free conditions are employed using appropriate mechano-chemical techniques as described.